Open an account

Precision BioSciences

DTIL · NASDAQ

$6.56+$0.37 (+5.98%)TodayMarket closed ·
Prev close $6.19

DTIL analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy3
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 7 analysts

Average $29.99 (+357.1% upside)

Low
$18.18
Now
$6.56
High
$63.00

Upgrades and downgrades

The latest rating actions, newest first

DTIL analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Aug 3, 2026MaintainsBuy
HC Wainwright & Co.Jul 9, 2026MaintainsBuy
OppenheimerJun 9, 2026InitiatesOutperform
HC Wainwright & Co.May 27, 2026MaintainsBuy
Jones TradingApr 17, 2026InitiatesBuy

The case for and against

Updated Oct 17, 2026

Bull case

Precision BioSciences is fundamentally attractive because its ARCUS platform is already producing differentiated clinical evidence in two wholly owned, high-value programs: PBGENE-HBV and PBGENE-DMD. In HBV, the company has delivered the first clinical evidence of direct cccDNA elimination across 38 doses in 16 patients, with all 6/6 baseline-pgRNA-positive patients becoming undetectable and HBsAg declining in 15/15 evaluable patients, supporting a potential finite viral-cure path rather than chronic suppression. In DMD, a single AAV9/ARCUS approach targets up to ~60% of patients and has shown strong preclinical restoration, making the company’s risk/reward profile compelling despite near-term clinical risk.

Bear case

Precision BioSciences is viewed negatively because its valuation still depends on highly uncertain clinical execution, with only a 20% probability of success assigned to PBGENE-DMD and meaningful efficacy not expected until early 2027. The business also appears dependent on future financing, including roughly $100M of gross equity raises in 2027E that could dilute shareholders, while the model assumes ARCUS-related revenues only beginning in 2030. Even with FDA clearance in February and sites now active, the imminent first dosing offers limited proof that the starting dose will be efficacious, leaving substantial clinical and financing risk unresolved.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.